Literature DB >> 24108131

Fish oil supplementation ameliorates fructose-induced hypertriglyceridemia and insulin resistance in adult male rhesus macaques.

Andrew A Bremer1, Kimber L Stanhope, James L Graham, Bethany P Cummings, Steve B Ampah, Benjamin R Saville, Peter J Havel.   

Abstract

Fish oil (FO) is a commonly used supplemental source of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 2 n-3 (ω-3) polyunsaturated fatty acids (PUFAs) that have been shown to have a variety of health benefits considered to be protective against cardiometabolic diseases. Although the effects of EPA and DHA on lipid metabolism have been extensively studied, not all of the metabolic effects of FO-derived n-3 PUFAs have been characterized. Our laboratory recently showed that a high-fructose diet in rhesus monkeys induces the features of metabolic syndrome (MetS) similar to those observed in humans. Thus, we specifically wanted to evaluate the effects of FO in rhesus monkeys fed a high-fructose diet and hypothesized that FO supplementation would mitigate the development of fructose-induced insulin resistance, dyslipidemia, and other cardiometabolic risk factors. In this study, adult monkeys (aged 12-20 y) received either a standard unpurified diet plus 75 g fructose/d (control group; n = 9) or a standard unpurified diet, 75 g fructose/d, and 4 g FO (16% EPA + 11% DHA)/d (treatment group; n = 10) for 6 mo. Importantly, our results showed that daily FO supplementation in the monkeys prevented fructose-induced hypertriglyceridemia and insulin resistance as assessed by intravenous-glucose-tolerance testing (P ≤ 0.05). Moreover, FO administration in the monkeys prevented fructose-induced increases in plasma apolipoprotein (Apo)C3, ApoE, and leptin concentrations and attenuated decreases in circulating adropin concentrations (P ≤ 0.05). No differences between the control and FO-treated monkeys were observed in body weight, lean mass, fat mass, or fasting glucose, insulin, and adiponectin concentrations. In conclusion, FO administration in a nonhuman primate model of diet-induced MetS ameliorates many of the adverse changes in lipid and glucose metabolism induced by chronic fructose consumption.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24108131      PMCID: PMC3861794          DOI: 10.3945/jn.113.178061

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  52 in total

Review 1.  (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?

Authors:  Dariush Mozaffarian; Jason H Y Wu
Journal:  J Nutr       Date:  2012-01-25       Impact factor: 4.798

2.  Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia.

Authors:  A A Rivellese; A Maffettone; C Iovine; L Di Marino; G Annuzzi; M Mancini; G Riccardi
Journal:  Diabetes Care       Date:  1996-11       Impact factor: 19.112

3.  Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes.

Authors:  Andrew A Bremer; Kimber L Stanhope; James L Graham; Bethany P Cummings; Wenli Wang; Benjamin R Saville; Peter J Havel
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

Review 4.  Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.

Authors:  Dariush Mozaffarian; Jason H Y Wu
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

5.  Dietary (n-3) long chain polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats.

Authors:  Ahamed Ibrahim; Laxmi Rajkumar; Vani Acharya
Journal:  J Nutr       Date:  2005-11       Impact factor: 4.798

Review 6.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

7.  Docosahexaenoic acid suppresses apolipoprotein A-I gene expression through hepatocyte nuclear factor-3β.

Authors:  Yu-Lin Kuang; K Eric Paulson; Alice H Lichtenstein; Nirupa R Matthan; Stefania Lamon-Fava
Journal:  Am J Clin Nutr       Date:  2011-06-08       Impact factor: 7.045

Review 8.  (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights.

Authors:  Nishan S Kalupahana; Kate J Claycombe; Naima Moustaid-Moussa
Journal:  Adv Nutr       Date:  2011-06-28       Impact factor: 8.701

Review 9.  Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism.

Authors:  Peter J Havel
Journal:  Nutr Rev       Date:  2005-05       Impact factor: 7.110

Review 10.  Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals.

Authors:  Gerald M Reaven
Journal:  Endocrinol Metab Clin North Am       Date:  2005-03       Impact factor: 4.741

View more
  24 in total

1.  Setting fire to fat.

Authors:  Zhihui Zhang; Min-Dian Li
Journal:  J Biol Chem       Date:  2019-06-21       Impact factor: 5.157

2.  A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.

Authors:  Kimber L Stanhope; Valentina Medici; Andrew A Bremer; Vivien Lee; Hazel D Lam; Marinelle V Nunez; Guoxia X Chen; Nancy L Keim; Peter J Havel
Journal:  Am J Clin Nutr       Date:  2015-04-22       Impact factor: 7.045

Review 3.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

Review 4.  Nitro-fatty acids: New drug candidates for chronic inflammatory and fibrotic diseases.

Authors:  Francisco J Schopfer; Dario A Vitturi; Diane K Jorkasky; Bruce A Freeman
Journal:  Nitric Oxide       Date:  2018-06-23       Impact factor: 4.427

5.  Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction.

Authors:  Subhashis Banerjee; Sarbani Ghoshal; Joseph R Stevens; Kyle S McCommis; Su Gao; Mauricio Castro-Sepulveda; Maria L Mizgier; Clemence Girardet; K Ganesh Kumar; Jose E Galgani; Michael L Niehoff; Susan A Farr; Jinsong Zhang; Andrew A Butler
Journal:  J Biol Chem       Date:  2020-07-29       Impact factor: 5.157

6.  Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi.

Authors:  Andrew A Butler; James L Graham; Kimber L Stanhope; So Wong; Sarah King; Andrew A Bremer; Ronald M Krauss; James Hamilton; Peter J Havel
Journal:  J Lipid Res       Date:  2020-01-09       Impact factor: 5.922

7.  Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates.

Authors:  Andrew A Butler; Jinsong Zhang; Candice A Price; Joseph R Stevens; James L Graham; Kimber L Stanhope; Sarah King; Ronald M Krauss; Andrew A Bremer; Peter J Havel
Journal:  J Biol Chem       Date:  2019-04-15       Impact factor: 5.157

8.  Acute suppression of insulin resistance-associated hepatic miR-29 in vivo improves glycemic control in adult mice.

Authors:  Yu-Han Hung; Matt Kanke; C Lisa Kurtz; Rebecca Cubitt; Rodica P Bunaciu; Ji Miao; Liye Zhou; James L Graham; M Mahmood Hussain; Peter Havel; Sudha Biddinger; Phillip J White; Praveen Sethupathy
Journal:  Physiol Genomics       Date:  2019-06-28       Impact factor: 3.107

Review 9.  Use and Importance of Nonhuman Primates in Metabolic Disease Research: Current State of the Field.

Authors:  Peter J Havel; Paul Kievit; Anthony G Comuzzie; Andrew A Bremer
Journal:  ILAR J       Date:  2017-12-01

Review 10.  Animal models of obesity and diabetes mellitus.

Authors:  Maximilian Kleinert; Christoffer Clemmensen; Susanna M Hofmann; Mary C Moore; Simone Renner; Stephen C Woods; Peter Huypens; Johannes Beckers; Martin Hrabe de Angelis; Annette Schürmann; Mostafa Bakhti; Martin Klingenspor; Mark Heiman; Alan D Cherrington; Michael Ristow; Heiko Lickert; Eckhard Wolf; Peter J Havel; Timo D Müller; Matthias H Tschöp
Journal:  Nat Rev Endocrinol       Date:  2018-01-19       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.